1
|
Kaur J, Sridharr M. Key Insights on the Classification and Theranostic Applications of Magnetic Resonance Imaging Contrast Agents. ChemMedChem 2024; 19:e202300521. [PMID: 38246874 DOI: 10.1002/cmdc.202300521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 01/19/2024] [Accepted: 01/19/2024] [Indexed: 01/23/2024]
Abstract
Magnetic resonance imaging (MRI) is a non-invasive molecular imaging tool being extensively employed in clinical and biomedical research for the detection of a broad spectrum of diseases. This technique offers remarkable spatial resolution, good tissue penetration and a high soft tissue contrast. Contrast agents (CAs) have been regularly used in MRI tests to enhance the resolution of MR images and to visualize the diseased sites in the body. In the past years, considerable efforts have been devoted towards developing new theranostic MRI agents that can be tailored to integrate the targeting and therapeutic functions in a single agent. In this review, we have underlined the role of the MRI CAs in the developing field of 'theranostics' and their recent applications in the combined imaging and therapy of different types of tumors. In addition, this review also outlines the different categories of MRI CAs and their comprehensive classification based on different criteria such as chemical composition, relaxation mechanism and biodistribution with clinically relevant examples.
Collapse
Affiliation(s)
- Jasleen Kaur
- Amity Institute of Virology and Immunology, Amity University, Sector-125, Amity University, Noida, 201313, Uttar Pradesh, India
| | - Manasvini Sridharr
- LMU Biocenter, Martinsreid, Ludwig-Maximilians-Universität München, Ludwig-Maximilians-Universität München, Geschwister-Scholl-Platz 1, München, Germany
| |
Collapse
|
2
|
Yazdan M, Naghib SM, Mozafari MR. Liposomal Nano-Based Drug Delivery Systems for Breast Cancer Therapy: Recent Advances and Progresses. Anticancer Agents Med Chem 2024; 24:896-915. [PMID: 38529608 DOI: 10.2174/0118715206293653240322041047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Revised: 02/21/2024] [Accepted: 02/27/2024] [Indexed: 03/27/2024]
Abstract
Breast cancer is a highly prevalent disease on a global scale, with a 30% incidence rate among women and a 14% mortality rate. Developing countries bear a disproportionate share of the disease burden, while countries with greater technological advancements exhibit a higher incidence. A mere 7% of women under the age of 40 are diagnosed with breast cancer, and the prevalence of this ailment is significantly diminished among those aged 35 and younger. Chemotherapy, radiation therapy, and surgical intervention comprise the treatment protocol. However, the ongoing quest for a definitive cure for breast cancer continues. The propensity for cancer stem cells to metastasize and resistance to treatment constitute their Achilles' heel. The advancement of drug delivery techniques that target cancer cells specifically holds significant promise in terms of facilitating timely detection and effective intervention. Novel approaches to pharmaceutical delivery, including nanostructures and liposomes, may bring about substantial changes in the way breast cancer is managed. These systems offer a multitude of advantages, such as heightened bioavailability, enhanced solubility, targeted tumor destruction, and diminished adverse effects. The application of nano-drug delivery systems to administer anti-breast cancer medications is a significant subject of research. This article delves into the domain of breast cancer, conventional treatment methods, the incorporation of nanotechnology into managerial tactics, and strategic approaches aimed at tackling the disease at its core.
Collapse
Affiliation(s)
- Mostafa Yazdan
- Department of Nanotechnology, School of Advanced Technologies, Iran University of Science and Technology (IUST), Tehran, 1684613114, Iran
| | - Seyed Morteza Naghib
- Department of Nanotechnology, School of Advanced Technologies, Iran University of Science and Technology (IUST), Tehran, 1684613114, Iran
| | - M R Mozafari
- Australasian Nanoscience and Nanotechnology Initiative (ANNI), Monash University LPO, Clayton, VIC 3168, Australia
| |
Collapse
|
3
|
Huang M, Zhai BT, Fan Y, Sun J, Shi YJ, Zhang XF, Zou JB, Wang JW, Guo DY. Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy. Int J Nanomedicine 2023; 18:4275-4311. [PMID: 37534056 PMCID: PMC10392909 DOI: 10.2147/ijn.s410688] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2023] [Accepted: 06/19/2023] [Indexed: 08/04/2023] Open
Abstract
Breast cancer (BC) is the most prevalent type of cancer in the world and the main reason women die from cancer. Due to the significant side effects of conventional treatments such as chemotherapy and radiotherapy, the search for supplemental and alternative natural drugs with lower toxicity and side effects is of interest to researchers. Curcumin (CUR) is a natural polyphenol extracted from turmeric. Numerous studies have demonstrated that CUR is an effective anticancer drug that works by modifying different intracellular signaling pathways. CUR's therapeutic utility is severely constrained by its short half-life in vivo, low water solubility, poor stability, quick metabolism, low oral bioavailability, and potential for gastrointestinal discomfort with high oral doses. One of the most practical solutions to the aforementioned issues is the development of targeted drug delivery systems (TDDSs) based on nanomaterials. To improve drug targeting and efficacy and to serve as a reference for the development and use of CUR TDDSs in the clinical setting, this review describes the physicochemical properties and bioavailability of CUR and its mechanism of action on BC, with emphasis on recent studies on TDDSs for BC in combination with CUR, including passive TDDSs, active TDDSs and physicochemical TDDSs.
Collapse
Affiliation(s)
- Mian Huang
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Bing-Tao Zhai
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
- State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Yu Fan
- School of Basic Medicine, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Jing Sun
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Ya-Jun Shi
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Xiao-Fei Zhang
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Jun-Bo Zou
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Jia-Wen Wang
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| | - Dong-Yan Guo
- School of Pharmacy, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
- Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, Shaanxi University of Chinese Medicine, Xi’an, 712046, People’s Republic of China
| |
Collapse
|
4
|
Murugan B, Sagadevan S, Fatimah I, Oh WC, Motalib Hossain MA, Johan MR. Smart stimuli-responsive nanocarriers for the cancer therapy – nanomedicine. NANOTECHNOLOGY REVIEWS 2021; 10:933-953. [DOI: 10.1515/ntrev-2021-0067] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
Abstract
Abstract
Nanomedicine is ongoing current research in the applications of nanotechnology for cancer therapy. Simply from a technology perspective, this field of research has an enormous broadening and success to date. Recently, nanomedicine has also made inroads in the treatment of cancer. Stimuli-responsive nanoparticles are an emerging field of research because its targeting capacity is of great interest in the treatment of cancer. The responsive nanoparticles are efficient in encountering different internal biological stimuli (acidic, pH, redox, and enzyme) and external stimuli (temperature, ultrasounds, magnetic field, and light), which are used as smart nanocarriers for delivery of the chemotherapeutic and imaging agents for cancer therapy. In-depth, the responsive nanocarrier that responds to the biological cues is of pronounced interest due to its capability to provide a controlled release profile at the tumor-specific site. The outlook of this review focuses on the stimuli-responsive nanocarrier drug delivery systems in sequence to address the biological challenges that need to be evaluated to overcome conventional cancer therapy.
Collapse
Affiliation(s)
- Baranya Murugan
- Centre for Nanotechnology & Advanced Biomaterials, SASTRA Deemed-to-be University , Thanjavur , 613401 , India
- School of Chemical & Biotechnology, SASTRA Deemed-to-be University , Thanjavur , 613401 , India
| | - Suresh Sagadevan
- Nanotechnology & Catalysis Research Centre, University of Malaya , 50603 , Kuala Lumpur , Malaysia
| | - Is Fatimah
- Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Islam Indonesia, Kampus Terpadu UII , Jl. Kaliurang Km 14, Sleman , Yogyakarta , Indonesia
| | - Won-Chun Oh
- Department of Advanced Materials Science and Engineering, Hanseo University , Seosan-si , Chungnam , 356-706 , Republic of Korea
| | - Mohd Abd Motalib Hossain
- Nanotechnology & Catalysis Research Centre, University of Malaya , 50603 , Kuala Lumpur , Malaysia
| | - Mohd Rafie Johan
- Nanotechnology & Catalysis Research Centre, University of Malaya , 50603 , Kuala Lumpur , Malaysia
| |
Collapse
|
5
|
Ali Dheyab M, Abdul Aziz A, Jameel MS, Moradi Khaniabadi P. Recent Advances in Synthesis, Medical Applications and Challenges for Gold-Coated Iron Oxide: Comprehensive Study. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:2147. [PMID: 34443977 PMCID: PMC8399645 DOI: 10.3390/nano11082147] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Revised: 08/12/2021] [Accepted: 08/13/2021] [Indexed: 01/10/2023]
Abstract
Combining iron oxide nanoparticles (Fe3O4 NPs) and gold nanoparticles (Au NPs) in one nanostructure is a promising technique for various applications. Fe3O4 NPs have special supermagnetic attributes that allow them to be applied in different areas, and Au NPs stand out in biomaterials due to their oxidation resistance, chemical stability, and unique optical properties. Recent studies have generally defined the physicochemical properties of nanostructures without concentrating on a particular formation strategy. This detailed review provides a summary of the latest research on the formation strategy and applications of Fe3O4@Au. The diverse methods of synthesis of Fe3O4@Au NPs with different basic organic and inorganic improvements are introduced. The role and applicability of Au coating on the surface of Fe3O4 NPs schemes were explored. The 40 most relevant publications were identified and reviewed. The versatility of combining Fe3O4@Au NPs as an option for medical application is proven in catalysis, hyperthermia, biomedical imaging, drug delivery and protein separation.
Collapse
Affiliation(s)
- Mohammed Ali Dheyab
- Nano-Biotechnology Research and Innovation (NanoBRI), Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia;
- Nano-Optoelectronics Research and Technology Lab (NORLab), School of Physics, Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia
| | - Azlan Abdul Aziz
- Nano-Biotechnology Research and Innovation (NanoBRI), Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia;
- Nano-Optoelectronics Research and Technology Lab (NORLab), School of Physics, Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia
| | - Mahmood S. Jameel
- Nano-Biotechnology Research and Innovation (NanoBRI), Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia;
- Nano-Optoelectronics Research and Technology Lab (NORLab), School of Physics, Universiti Sains Malaysia, Pulau Pinang 11800, Malaysia
| | - Pegah Moradi Khaniabadi
- Department of Radiology and Molecular Imaging, College of Medicine and Health Science, Sultan Qaboos University, P.O. Box 35, Al Khod, Muscat 123, Oman;
| |
Collapse
|
6
|
Liang Y, Xie J, Yu J, Zheng Z, Liu F, Yang A. Recent advances of high performance magnetic iron oxide nanoparticles: Controlled synthesis, properties tuning and cancer theranostics. NANO SELECT 2020. [DOI: 10.1002/nano.202000169] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Affiliation(s)
- Yi‐Jun Liang
- School of Medical Engineering Foshan University Foshan 528000 P.R. China
| | - Jun Xie
- School of Life Science Jiangsu Normal University Xuzhou 221116 P.R. China
| | - Jing Yu
- College of Materials Science and Engineering Zhejiang University of Technology Hangzhou 310014 P.R. China
| | - Zhaoguang Zheng
- School of Medical Engineering Foshan University Foshan 528000 P.R. China
| | - Fang Liu
- School of Medical Engineering Foshan University Foshan 528000 P.R. China
| | - Anping Yang
- School of Medical Engineering Foshan University Foshan 528000 P.R. China
| |
Collapse
|
7
|
Recent advances in novel drug delivery systems and approaches for management of breast cancer: A comprehensive review. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101505] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
8
|
Yang M, Gu Y, Tang X, Wang T, Liu J. Advancement of Lipid-Based Nanocarriers and Combination Application with Physical Penetration Technique. Curr Drug Deliv 2019; 16:312-324. [PMID: 30657039 DOI: 10.2174/1567201816666190118125427] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2018] [Revised: 09/01/2018] [Accepted: 01/09/2019] [Indexed: 12/28/2022]
Abstract
On account of the advantages of transdermal delivery and the application situation of transcutaneous technology in transdermal delivery, the article critically comments on nanosystems as permeation enhancement model. Nanosystems possess great potential for transcutaneous drug delivery. This review focuses on recent advances in lipid-based nanocarriers, including liposome, transfersomes, ethosomes, nanoemulsions, solid lipid nanoparticles, nanostructured lipid carriers and combination application of the lipid-based nanocarriers with microneedle, iontophoresis, electroporation and sonophoresis in the field for the development of the transdermal drug delivery system. We attempted to give an overview of lipid-based nanocarriers with the aim to improve transdermal and dermal drug delivery. A special focus is given to the nanocarrier composition, characteristic and interaction mechanisms through the skin. Recent combination applications of lipid-based nanocarriers with the physical penetration technology demonstrate the superiority of the combined use of nanocarriers and physical methods in drug penetration enhancement compared to their single use. In the future, lipidbased nanocarriers will play a greater role in the field of transdermal and dermal drug delivery.
Collapse
Affiliation(s)
- Meng Yang
- Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.,Department of Pharmacy, Shanghai Ninth People Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, 200011, China
| | - Yongwei Gu
- College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, China
| | - Xiaomeng Tang
- Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China
| | - Ting Wang
- College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250355, China
| | - Jiyong Liu
- Department of Pharmacy, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.,Department of Pharmacy, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
| |
Collapse
|
9
|
Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK. Current trends and challenges in cancer management and therapy using designer nanomaterials. NANO CONVERGENCE 2019; 6:23. [PMID: 31304563 PMCID: PMC6626766 DOI: 10.1186/s40580-019-0193-2] [Citation(s) in RCA: 344] [Impact Index Per Article: 68.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 06/17/2019] [Indexed: 05/06/2023]
Abstract
Nanotechnology has the potential to circumvent several drawbacks of conventional therapeutic formulations. In fact, significant strides have been made towards the application of engineered nanomaterials for the treatment of cancer with high specificity, sensitivity and efficacy. Tailor-made nanomaterials functionalized with specific ligands can target cancer cells in a predictable manner and deliver encapsulated payloads effectively. Moreover, nanomaterials can also be designed for increased drug loading, improved half-life in the body, controlled release, and selective distribution by modifying their composition, size, morphology, and surface chemistry. To date, polymeric nanomaterials, metallic nanoparticles, carbon-based materials, liposomes, and dendrimers have been developed as smart drug delivery systems for cancer treatment, demonstrating enhanced pharmacokinetic and pharmacodynamic profiles over conventional formulations due to their nanoscale size and unique physicochemical characteristics. The data present in the literature suggest that nanotechnology will provide next-generation platforms for cancer management and anticancer therapy. Therefore, in this critical review, we summarize a range of nanomaterials which are currently being employed for anticancer therapies and discuss the fundamental role of their physicochemical properties in cancer management. We further elaborate on the topical progress made to date toward nanomaterial engineering for cancer therapy, including current strategies for drug targeting and release for efficient cancer administration. We also discuss issues of nanotoxicity, which is an often-neglected feature of nanotechnology. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field.
Collapse
Affiliation(s)
- P N Navya
- Nano-Bio Interfacial Research Laboratory (NBIRL), Department of Biotechnology, Siddaganga Institute of Technology, Tumkur, Karnataka, 572103, India.
- Department of Biotechnology, Bannari Amman Institute of Technology, Sathyamangalam, Erode, Tamil Nadu, 638401, India.
| | - Anubhav Kaphle
- Melbourne Integrative Genomics, School of BioSciences/School of Mathematics and Statistics, The University of Melbourne, Melbourne, VIC, 3010, Australia
| | - S P Srinivas
- School of Optometry, Indiana University, Bloomington, Indiana, 47405, USA
| | - Suresh Kumar Bhargava
- Centre for Advanced Materials and Industrial Chemistry, School of Science, RMIT University, Melbourne, VIC, 3001, Australia
| | - Vincent M Rotello
- Department of Chemistry, University of Massachusetts (UMass) Amherst, 710 North Pleasant Street, Amherst, MA, 01003, USA
| | - Hemant Kumar Daima
- Nano-Bio Interfacial Research Laboratory (NBIRL), Department of Biotechnology, Siddaganga Institute of Technology, Tumkur, Karnataka, 572103, India.
- Centre for Advanced Materials and Industrial Chemistry, School of Science, RMIT University, Melbourne, VIC, 3001, Australia.
- Amity Institute of Biotechnology, Amity University Rajasthan, Kant Kalwar, NH-11C, Jaipur-Delhi Highway, Jaipur, Rajasthan, 303002, India.
| |
Collapse
|
10
|
Evaluation of Chemical and Green Synthesized Iron Oxide Nanoparticles’ Associated Renal Toxicity in Different Experimental Models: A Comparative Study. J CLUST SCI 2019. [DOI: 10.1007/s10876-018-01492-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Li D, Shi M, Bao C, Bao W, Zhang L, Jiao L, Li T, Li Y. Synergistically enhanced anticancer effect of codelivered curcumin and siPlk1 by stimuli-responsive α-lactalbumin nanospheres. Nanomedicine (Lond) 2019; 14:595-612. [PMID: 30806584 DOI: 10.2217/nnm-2018-0291] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
AIM To achieve enhanced anticancer efficacy by combined siPlk1 and curcumin (cur) therapy using α-lactalbumin (α-lac) nanocarrier delivery. MATERIALS & METHODS α-Lac was partially hydrolyzed into amphiphilic peptides, and then self-assembled into nanospheres (NS). Cur was loaded into their hydrophobic core during the self-assembly process. siPlk1-SH was cross-linked with the endogenous cysteines on the NS. CRGDK peptide was conjugated on NS to target integrins overexpressed in HeLa cells. RESULTS & CONCLUSION The Cur and siPlk1 coloaded NS formulations possessed an enhanced tumor targeting and antitumor properties. Drugs were responsively released from disulfide bonds cross-linked RGD-NS/Cur/siPlk1 corresponding to the high intracellular glutathione concentrations of cancer cells. Both in vitro cell viability experiments and in vivo antitumor evaluations demonstrated that the codelivered nanosphere platform exhibited excellent tumor targeting and synergistic antitumor efficacy.
Collapse
Affiliation(s)
- Dan Li
- Beijing Advanced Innovation Center for Food Nutrition & Human Health, College of Food Science & Nutritional Engineering, China Agricultural University, 100083 Beijing, China
| | - Mengxuan Shi
- State Key Laboratory of Chemical Resource Engineering, College of Life Science & Technology, Beijing University of Chemical Technology, 100029 Beijing, China
| | - Cheng Bao
- State Key Laboratory of Chemical Resource Engineering, College of Life Science & Technology, Beijing University of Chemical Technology, 100029 Beijing, China
| | - Weier Bao
- State Key Laboratory of Chemical Resource Engineering, College of Life Science & Technology, Beijing University of Chemical Technology, 100029 Beijing, China
| | - Liwei Zhang
- Beijing Advanced Innovation Center for Food Nutrition & Human Health, College of Food Science & Nutritional Engineering, China Agricultural University, 100083 Beijing, China
| | - Lulu Jiao
- Beijing Advanced Innovation Center for Food Nutrition & Human Health, College of Food Science & Nutritional Engineering, China Agricultural University, 100083 Beijing, China
| | - Tao Li
- Beijing Advanced Innovation Center for Food Nutrition & Human Health, College of Food Science & Nutritional Engineering, China Agricultural University, 100083 Beijing, China
| | - Yuan Li
- Beijing Advanced Innovation Center for Food Nutrition & Human Health, College of Food Science & Nutritional Engineering, China Agricultural University, 100083 Beijing, China
| |
Collapse
|
12
|
Zhang L, Tan S, Liu Y, Xie H, Luo B, Wang J. In vitro inhibition of tumor growth by low-dose iron oxide nanoparticles activating macrophages. J Biomater Appl 2019; 33:935-945. [DOI: 10.1177/0885328218817939] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Macrophages as immunocyte are attracting more and more attention in cancer therapy. Our previous study observed that dimercaptosuccinic acid (DMSA)-coated Fe3O4 magnetic nanoparticles triggered comprehensive immune responses of mouse macrophages (RAW264.7 cells) and induced production of many kinds of cytokines. This study investigated the effects of Fe3O4 magnetic nanoparticles on RAW264.7 cells proliferation, migration, and inhibition of tumor growth in vitro. Fe3O4 magnetic nanoparticles had an average size of about 11 nm with good dispersibility and uniformity. Fe3O4 magnetic nanoparticles internalized efficiently into RAW264.7 cells. Through Cell Counting Kit-8 (CCK-8) detection, the proliferation of RAW264.7 cells significantly increased by the low-dose Fe3O4 magnetic nanoparticles (50 µg/mL) treatment. The results of wound-healing and Transwell assays both displayed a significant promotion of the RAW264.7 cells migratory capability compared with control group ( P<0.01). It is interesting to find that a large number of proliferated RAW264.7 cells were activated to surround quickly and attack mouse liver cancer cell (Hepa1-6) cells by Fe3O4 magnetic nanoparticles. The growth of Hepa1-6 cells was effectively inhibited according to microscope imaging and flow cytometry analysis. The inhibition may be cooperative effects of RAW264.7 cells proliferation, migration, and immune activation. The results suggest potential clinical value of low-dose iron oxide nanomaterials in cancer therapy.
Collapse
Affiliation(s)
- Ling Zhang
- School of Biomedical Engineering, Hubei University of Science and Technology, Xianning, China
- State Key Laboratory of Bioelectronics, Southeast University, Nanjing, China
| | - Shengwei Tan
- School of life sciences, Nantong University, Nantong, China
| | - Yingxun Liu
- School of Biomedical Engineering, Hubei University of Science and Technology, Xianning, China
- State Key Laboratory of Bioelectronics, Southeast University, Nanjing, China
| | - Hongmei Xie
- School of Biomedical Engineering, Hubei University of Science and Technology, Xianning, China
- State Key Laboratory of Bioelectronics, Southeast University, Nanjing, China
| | - Binhua Luo
- School of Pharmacy, Hubei University of Science and Technology, Xianning, China
| | - Jinke Wang
- School of Biomedical Engineering, Hubei University of Science and Technology, Xianning, China
- State Key Laboratory of Bioelectronics, Southeast University, Nanjing, China
| |
Collapse
|